<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/21/genprex-nasdaqgnpx-stock-price-down-43-5.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-21T20:38:45+00:00"/>
    <meta property="og:title" content="Genprex (NASDAQ:GNPX) Stock Price Down 43.5%"/>
    <meta property="og:description" content="Shares of Genprex Inc (NASDAQ:GNPX) fell 43.5% during trading on Thursday . The company traded as low as $0.32 and last traded at $0.35, 4,369,400 shares changed hands during trading. An increase of 3,439% from the average session volume of 123,465 shares. The stock had previously closed at $0.62. Separately, ValuEngine upgraded shares of Genprex […]"/>
  </head>
  <body>
    <article>
      <h1>Genprex (NASDAQ:GNPX) Stock Price Down 43.5%</h1>
      <address><time datetime="2019-11-21T20:38:45+00:00">21 Nov 2019, 20:38</time> by <a rel="author" href="https://www.thecerbatgem.com/author/jessica" target="_blank">Jessica Moore</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/generic-stocks.jpg"/>
      </figure>
      <p>Shares of Genprex Inc (NASDAQ:GNPX) fell 43.5% during trading on Thursday . The company traded as low as $0.32 and last traded at $0.35, 4,369,400 shares changed hands during trading. An increase of 3,439% from the average session volume of 123,465 shares. The stock had previously closed at $0.62.</p>
      <p>Separately, <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=GNPX">ValuEngine</a> upgraded shares of Genprex from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.</p>
      <p>The stock has a market cap of $6.38 million, a P/E ratio of -0.33 and a beta of 1.36. The stock’s fifty day moving average price is $0.51 and its 200 day moving average price is $1.02.</p>
      <p>An institutional investor recently bought a new position in Genprex stock. Citadel Advisors LLC bought a new stake in shares of Genprex Inc (NASDAQ:GNPX) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 31,529 shares of the company’s stock, valued at approximately $39,000. Citadel Advisors LLC owned approximately 0.20% of Genprex at the end of the most recent quarter. Institutional investors own 12.86% of the company’s stock.</p>
      <p><b>Genprex Company Profile</b> (<a href="https://www.marketbeat.com/stocks/NASDAQ/GNPX/">NASDAQ:GNPX</a>)</p>
      <p>Genprex, Inc operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells.</p>
      <p>Featured Article: <a href="https://www.marketbeat.com/earnings/latest/">What are earnings reports?</a></p>
    </article>
  </body>
</html>